N/A
Completed N=312
A Study of Bimatoprost 0.01% in the Clinical Setting
Glaucoma, Primary Open Angle · Hypertension
Source: ClinicalTrials.gov NCT01814761 ↗
Enrolled (actual)
312
Serious AEs
1.0%
Results posted
Oct 2015
Primary outcomePrimary: Severity of Ocular Hyperemia in the Study Eye on a 5-Point Scale — 7; 36; 10; 50 Patients
Summary
This is a study of bimatoprost 0.01% (LUMIGAN® 0.01%) in subjects with primary open-angle glaucoma (POAG) or ocular hypertension (OH) who require further treatment for elevated intraocular pressure (IOP).
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Severity of Ocular Hyperemia in the Study Eye on a 5-Point Scale |
7; 36; 10; 50; 12; 84 | — |
| SECONDARY Change From Baseline in Intraocular Pressure (IOP) in the Study Eye |
18.0; 17.8; -3.6; -2.6 | — |
| SECONDARY Percentage of Patients Who Discontinue Due to an Adverse Event |
14.3; 5.6 | — |
| SECONDARY Overall Percent Change From Baseline in IOP |
-19.25; -13.26 | — |
Eligibility Criteria
Inclusion Criteria
- Diagnosis of primary open-angle glaucoma or ocular hypertension
- Determined by the treating physician to require treatment with bimatoprost 0.01%.
Exclusion Criteria
- Previous use of Lumigan® 0.01%
Data sourced from ClinicalTrials.gov (NCT01814761). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.